NKTX
Nkarta·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NKTX
Nkarta, Inc.
A biotech company developing natural killer cell therapies for cancer and infectious diseases
1150 Veterans Boulevard, South San Francisco, CA 94080
--
Nkarta, Inc., was incorporated in Delaware in July 2015. The Company is a clinical-stage biopharmaceutical company dedicated to the development of allogeneic, off-the-shelf engineered natural killer (" NK ") cell therapies for the treatment of patients with autoimmune diseases or hematological malignancies. The company was founded on the belief that engineered NK cell therapies can transform patients' lives by providing therapies that are clinically meaningful, widely accessible and not subject to safety concerns associated with other cell therapy approaches.
Company Financials
EPS
NKTX has released its 2025 Q3 earnings. EPS was reported at -0.29, versus the expected -0.3, beating expectations. The chart below visualizes how NKTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
